Form 4: Xeris Biopharma Holdings CEO John Patrick Shannon Jr. Reports Stock Disposal for Tax Obligations
SEC Form 4 Filing
John Patrick Shannon Jr., CEO of Xeris Biopharma Holdings, disposed of shares to cover income tax obligations related to vested Restricted Stock Units.
Summary
- On January 3, 2025, John Patrick Shannon Jr., CEO of Xeris Biopharma Holdings, disposed of 39,443 shares of common stock to satisfy income tax obligations.
- The shares were withheld by the issuer in connection with the net settlement of Restricted Stock Units that vested on the same date.
- The transaction was executed at a price of $3.61 per share.
- Following the transaction, Shannon directly owns 2,108,618 shares of Xeris Biopharma Holdings.
Sentiment
Score: 5
Explanation: Neutral sentiment as the filing reflects a routine transaction for tax purposes.
Industry Context
Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, providing transparency to investors.
Stakeholder Impact
- The transaction has a minimal impact on shareholders as it is a standard procedure for covering tax obligations.
Key Dates
| Date | Description |
|---|---|
| 01/03/2025 | Date of stock disposal and vesting of Restricted Stock Units |
| 01/07/2025 | Date of signature on the Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.